SCHEMBL24399762

SCHEMBL24399762

Cc1ccc2c(Nc3cc(F)ccc3F)nccc2c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.40
PIM1 P11309 2/20 0.37
PIM2 Q9P1W9 2/20 0.37
GRM4 Q14833 1/20 0.37
FERMT2 Q96AC1 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
LRRK2 Q5S007 1/20 0.36
CSF1R P07333 2/20 0.35
BRAF P15056 2/20 0.35
RAF1 P04049 1/20 0.35
DDR1 Q08345 1/20 0.35
DDR2 Q16832 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24399688 0.90 FGFR1 (0.44) PIM1PIM2FERMT2CCNCCDK8
SCHEMBL24399614 0.89 ADORA2A (0.46) PIM1PIM2GRM4CSF1RBRAF
SCHEMBL26210662 0.88 EGFR (0.45) GRM4CSF1RBRAFRAF1DDR1
SCHEMBL24399714 0.87 EGFR (0.36) LRRK2CSF1RBRAFRAF1DDR1
SCHEMBL29638638 0.87 EGFR (0.36) LRRK2CSF1RBRAFRAF1DDR1
SCHEMBL26210446 0.85 EGFR (0.39) FERMT2BRAFRAF1ALDH1A1CCNB2
SCHEMBL30400458 0.84 BACE2 (0.39) CSF1RBRAFRAF1DDR1DDR2
SCHEMBL25374814 0.84 BACE2 (0.39) CSF1RBRAFRAF1DDR1DDR2
SCHEMBL26207960 0.84 LRRK2 (0.48) PIM1PIM2CCNCCDK8LRRK2
SCHEMBL30559487 0.83 TNNI3K (0.43) CSF1RBRAFRAF1DDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
EP-4238967-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2023-09-06 EP disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM DHFR 285/4885PIM1 2032/4885PIM2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.